Participated · Equity · Jan 2020

Sonendo, based in Laguna Hills, California and founded in 2006 by Fjord Ventures, develops innovative technologies for dentists. Its flagship GentleWave® System offers an alternative to traditional root canal treatment and departs from standard file-based cleaning techniques. The company reports that over 300,000 patients have been treated with the GentleWave System. Sonendo is also the parent company of TDO® Software, an endodontic practice management platform that integrates practice management, imaging, social media, referral reporting, CBCT imaging and communication with the GentleWave System. The company is led by President and CEO Bjarne Bergheim and continues to develop and expand its dental technology offerings. Sonendo develops dental technologies focused on improving root canal treatment, with its flagship GentleWave® System offering an alternative to standard file-based methods of tissue removal and disinfection. The GentleWave System is available in the US. The company is led by President and CEO Bjarne Bergheim and is based in Laguna Hills, Calif. Sonendo raised $50M in growth funding to support its commercial trajectory. The company intends to use the proceeds to accelerate ongoing commercialization efforts and to expand and diversify its current product portfolio. No operating metrics were disclosed in the article. Sonendo is a Laguna Hills, California developer of dental technology centered on the GentleWave® System. The company positions the GentleWave System as an alternative to standard root canal treatment and, available in the U.S., shows significant improvements in clinical efficacy and treatment efficiency compared with standard techniques. Led by President and CEO Bjarne Bergheim, Sonendo intends to use new funding to advance commercialization of the GentleWave System. It also plans to develop additional products in adjacent verticals. Sonendo completed a $35M equity financing to support these efforts, and Michael Zhao of DiNovA Capital joined the company’s board in conjunction with the financing. Sonendo, based in Laguna Hills, California, develops technology for the endodontic marketplace, principally the GentleWave System for root canal therapy. The GentleWave System is 510(k) FDA cleared, debuted at the American Association of Endodontists annual meeting in May, and is currently in limited market release. Led by President and CEO Bjarne Bergheim, the company is launching the system and aims to change the standard of care for root canal procedures. Sonendo completed a $35m equity financing to support further technology development, fund clinical studies, and commercialize the GentleWave System. The company previously closed a $10m debt financing with Oxford Finance in April 2014 and raised $18m in venture capital in June 2013. Paul Madera of Meritech Capital Partners joined Sonendo’s board in conjunction with the round. Sonendo develops technology for the endodontic marketplace, focusing on systems to transform traditional endodontic therapy. Its core product is the Multisonic Ultracleaning System, which is set to launch in 2014. The company closed a $10M venture debt facility intended to commercialize that system. Sonendo is led by President and CEO Bjarne Bergheim. Investors in the company include OrbiMed Advisors LLC, Themes Investment Partners, Fjord Ventures, NeoMed Management and Oxford Finance LLC. The company is based in Laguna Hills, California.

Participated · Equity · Feb 2015

Cortendo is a global biopharmaceutical company focused on orphan endocrine disorders and cortisol inhibition. Its lead investigational drug, COR-003 (levoketoconazole), is being studied in the global Phase 3 SONICS trial for endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the EMA and the FDA. The company intends to independently commercialize its orphan/endocrine assets in key markets and to partner non-strategic opportunities such as diabetes at relevant stages. Cortendo is incorporated in Sweden and based in the United States. Recent financings — including the latest private placement — are intended to strengthen the company’s ability to drive enrollment in the Phase 3 trial and to support partnering efforts.